Literature DB >> 32478487

Comparison of MAFLD and NAFLD diagnostic criteria in real world.

Su Lin1, Jiaofeng Huang1, Mingfang Wang1, Rahul Kumar2, Yuxiu Liu1, Shiying Liu1, Yinlian Wu1, Xiaozhong Wang3, Yueyong Zhu1.   

Abstract

BACKGROUND AND AIMS: Metabolic associated fatty liver disease (MAFLD) is a novel concept proposed in 2020, the utility of which has not been tested and validated in real world. We aimed to compare the characteristics of MAFLD and non-alcoholic fatty liver disease (NAFLD).
METHODS: The data was retrieved from the third National Health and Nutrition Examination Surveys of the United States, which is an unbiased survey dataset and frequently used for the study of fatty liver disease.
RESULTS: A total of 13 083 cases with completed ultrasonography and laboratory data were identified from the NHANES III database. MAFLD was diagnosed in 4087/13 083 (31.24%) participants, while NAFLD in 4347/13 083 (33.23%) amongst the overall population and 4347/12 045 (36.09%) in patients without alcohol intake and other liver diseases. Compared with NAFLD, MAFLD patients were significantly older, had higher BMI level, higher proportions of metabolic comorbidities (diabetes, hypertension) and higher HOMA-IR, lipid and liver enzymes. MAFLD patients with alcohol consumption were younger than those without, and more likely to be male. They had less metabolic disorder but higher liver enzymes. There were more cases with advance fibrosis in MAFLD patients with alcohol consumption.
CONCLUSION: MAFLD definition is more practical for identifying patients with fatty liver disease with high risk of disease progression.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  NHANES; diagnosis; metabolic associated fatty liver disease; non-alcoholic fatty liver disease

Mesh:

Year:  2020        PMID: 32478487     DOI: 10.1111/liv.14548

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  72 in total

Review 1.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Authors:  Ting-Yao Wang; Rui-Fang Wang; Zhi-Ying Bu; Giovanni Targher; Christopher D Byrne; Dan-Qin Sun; Ming-Hua Zheng
Journal:  Nat Rev Nephrol       Date:  2022-01-10       Impact factor: 28.314

2.  Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018.

Authors:  Yunlei Deng; Qianwen Zhao; Rong Gong
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-22       Impact factor: 3.168

3.  Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.

Authors:  Yu-Ling Chen; Hao Li; Shu Li; Zhou Xu; Shen Tian; Juan Wu; Xin-Yu Liang; Xin Li; Zi-Li Liu; Jun Xiao; Jia-Ying Wei; Chen-Yu Ma; Kai-Nan Wu; Liang Ran; Ling-Quan Kong
Journal:  BMC Gastroenterol       Date:  2021-05-10       Impact factor: 3.067

4.  Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease.

Authors:  Mi Na Kim; Kyungdo Han; Juhwan Yoo; Yeonjung Ha; Young Eun Chon; Ju Ho Lee; Tracey G Simon; Andrew T Chan; Seong Gyu Hwang
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

5.  Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Shang-Chin Huang; Hau-Jyun Su; Jia-Horng Kao; Tai-Chung Tseng; Hung-Chih Yang; Tung-Hung Su; Pei-Jer Chen; Chun-Jen Liu
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

6.  Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.

Authors:  Shuhei Fukunaga; Dan Nakano; Takumi Kawaguchi; Mohammed Eslam; Akihiro Ouchi; Tsutomu Nagata; Hidefumi Kuroki; Hidemichi Kawata; Hirohiko Abe; Ryuichi Nouno; Koutaro Kawaguchi; Jacob George; Keiichi Mitsuyama; Takuji Torimura
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

7.  Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).

Authors:  Nahum Méndez-Sánchez; Luis Enrique Díaz-Orozco
Journal:  Med Sci Monit       Date:  2021-07-12

8.  NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III.

Authors:  Qi Huang; Xiantong Zou; Xin Wen; Xianghai Zhou; Linong Ji
Journal:  Front Med (Lausanne)       Date:  2021-07-01

9.  Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity.

Authors:  Mona A Hegazy; Ibrahim Abd ALgwad; Soheir Abuel Fadl; Mohamed Sayed Hassan; Laila Ahmed Rashed; Maha A Hussein
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-19       Impact factor: 3.168

10.  MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.

Authors:  Jiaofeng Huang; Wenjuan Xue; Mingfang Wang; Yinlian Wu; Medha Singh; Yueyong Zhu; Rahul Kumar; Su Lin
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-27       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.